Background
==========

The human fibroblast growth factor (FGF) and its receptor families consist of 22 structurally related FGF members and four high-affinity tyrosine kinase FGF receptors (FGFR1 to 4) \[[@B1],[@B2]\]. The four FGFRs generate ligand-binding specific isoforms by tissue-specific alternative mRNA splicing of the genes \[[@B3]-[@B7]\]. FGFs and their receptors have an important role in cell signaling \[[@B8]\]. The formation of the FGF-FGFR complex activates the intracellular tyrosine kinase, which mediates signal transduction through the direct phosphorylation of adaptor proteins \[[@B9]\]. These complex FGF signaling networks are crucial in the multiple cell biological activities, such as proliferation, differentiation, mitogenesis, migration, and apoptosis, and are thus implicated in tumorigenesis \[[@B10]-[@B12]\].

The *FGFR2*, known as a unique high-affinity receptor for keratinocyte growth factor (KGF or FGF7), is expressed in the keratinocytes of the skin epidermis, hair follicles, and mesenchymal tissues \[[@B5],[@B13],[@B14]\]. An experiment in transgenic mice with *FGFR2*mutation in the keratinocyte showed that normal signal transduction was blocked by binding of its ligand KGF \[[@B15]\]. It has been reported that the *FGFR2*plays a role in tumor suppression in the skin \[[@B16]\]. In addition, the increased *FGFR2*gene expression has been related to the genetic variants in intron 2 of the *FGFR2*gene \[[@B17]\] and deregulation of *FGFR2*gene expression and/or gene mutation has been identified in various kinds of human cancers, such as breast, prostate, endometrial, colon, bladder, and thyroid cancers \[[@B17]-[@B22]\]. Recently, two genome-wide association studies have identified some genetic variants in the *FGFR2*gene that were highly associated with breast cancer \[[@B23],[@B24]\].

The *FGFR4*gene located on the chromosome 5 spans approximately 11.3 kb and is composed of 18 exons \[[@B25]\]. Overexpression of the FGFR4 protein has been associated with cutaneous melanoma progression \[[@B26]\]. High expression of FGFR4 has also been observed in breast cancer, prostate cancer, pancreatic cancer, and renal cell carcinoma \[[@B27]-[@B30]\]. Furthermore, SNP rs351855 located in exon 9 of the *FGFR4*gene results in an amino acid change (Gly388Arg) in the transmembrane domain of the receptor and has been associated with tumor progression in, for example, cutaneous nodular malignant melanoma, breast cancer, lung adenocarcinoma, prostate cancer, and head and neck cancer \[[@B26],[@B31]-[@B36]\].

We conducted a nested case-control study of Caucasians within the Nurses\' Health Study (NHS) to evaluate whether the four breast cancer-related SNPs in the *FGFR2*gene (rs11200014, rs2981579, rs1219648, and rs2420946) \[[@B24]\] and the three common variants (tag-SNPs) in the *FGFR4*gene (rs1966265, rs376618, and rs351855) are associated with the risk of three skin cancer types including melanoma, squamous cell carcinoma (SCC), and basal cell carcinoma (BCC).

Methods
=======

Eligible cases in this study consisted of women with incident skin cancer from the subcohort of the NHS who gave a blood specimen in 1989--1990 (*n*= 32,826), including SCC and BCC cases with a diagnosis any time after blood collection up to June 1, 1998 and melanoma cases up to June 1, 2000 with no previously diagnosed skin cancer. A common control series was randomly selected from participants who gave a blood sample and were free of diagnosed skin cancer up to and including the questionnaire cycle during which the case was diagnosed. One or two controls were matched to each case by year of birth (± 1 year). All subjects were drawn from the U.S. non-Hispanic Caucasian women in this study. The nested case-control study consisted of 218 incident melanoma cases, 285 incident SCC cases, a sample of 300 BCC cases from the large number of incident cases, and 870 age-matched controls. The informed consent was obtained from the participants in this study. The study protocol was approved by the Committee on Use of Human Subjects of the Brigham and Women\'s Hospital, Boston, MA.

We obtained information regarding skin cancer risk factors from the prospective biennial questionnaires and a retrospective supplementary questionnaire. Information on natural hair color at age 20 and childhood and adolescent tanning tendency were collected in the 1982 prospective questionnaire. Ethnic group was ascertained in the 1992 questionnaire. In the skin cancer nested case-control study, natural skin color and other sun exposure-related information were collected by the retrospective supplementary questionnaire in 2002. The response rates of cases and controls were 92% and 89%, respectively. A cumulative lifetime sun exposure while wearing a bathing suit for each individual was developed by combining the UV database and the information obtained from the supplementary questionnaires. We constructed a multivariate confounder score to create a constitutional susceptibility score \[[@B37]\], summarizing natural skin color, natural hair color, child or adolescent tendency to burn, and the number of palpably raised moles on arms. We used this score to define women with constitutional susceptibility \[[@B38]\]. In addition, the 11 states of residence of cohort members at baseline were grouped into three regions: Northeast (Connecticut, Massachusetts, Maryland, New Jersey, New York, and Pennsylvania), Northcentral (Michigan and Ohio), and West and South (California, Texas, and Florida).

Information on the seven SNPs in the *FGFR2*and *FGFR4*genes is presented in Table [1](#T1){ref-type="table"}. Four SNPs in intron 2 of the *FGFR2*gene (rs11200014, rs2981579, rs1219648, and rs2420946) genotyped in this study were breast cancer-related SNPs identified by a recent genome-wide association study conducted by our group \[[@B24]\]. For the *FGFR4*gene, based on the HapMap phase II SNP genotype data, we chose three tag-SNPs (rs1966265, rs376618, and rs351855) as surrogates for untyped polymorphisms in the *FGFR4*gene using the HapMap Project 90 (30 trios) Caucasian samples from a US Utah population with Northern and Western European ancestry collected in 1980 by the Centre d\'Etude du Polymorphisme Humain (CEPH) \[[@B39]\]. Briefly, the tag-SNPs (minor allele frequency \> 0.05) were selected using the Tagger program of (r^2^\>0.8), which combines the simplicity of pairwise r^2^methods \[[@B40]\] with the potential efficiency of multimarker haplotype approaches \[[@B41]\].

###### 

Seven SNPs in the *FGFR2*and *FGFR4*genes

  SNP                rs\#           Chromosome   Location    MAF-controls (%)^a^   MAF-CEU (%)^b^
  ------------------ -------------- ------------ ----------- --------------------- ----------------
  *FGFR2*intron 2    rs11200014     10           123324920   42                    47
  *FGFR2*intron 2    rs2981579      10           123327325   42                    47
  *FGFR2*intron 2    rs1219648      10           123336180   40                    47
  *FGFR2*intron 2    rs2420946      10           123341314   40                    47
  *FGFR4*Val10Ile    rs1966265\*    5            176449237   \-                    20
                     rs12519145\*   5            176488129   22                    19
  *FGFR4*Leu136Pro   rs376618       5            176450403   24                    26
  *FGFR4*Gly388Arg   rs351855       5            176452849   31                    28

\*The SNP rs1966265 failed the assay and the rs12519145 was genotyped instead (r^2^= 0.8).

^a^Minor allele frequency (MAF) was calculated among controls in this study.

^b^MAF was based on the HapMap CEU (Utah residents with ancestry from northern and western Europe) samples.

We genotyped these seven SNPs by the 5\' nuclease assay (TaqMan^®^) in 384-well format, using the ABI PRISM 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA). TaqMan^®^primers and probes were designed with the Primer Express^®^Oligo Design software v2.0 (ABI PRISM). Due to assay failure, we genotyped rs12519145 as a surrogate for the *FGFR4*rs1966265 (r^2^= 0.8). Laboratory personnel were blinded to case-control status, and 10% blinded quality control samples (duplicate samples) were inserted to validate genotyping procedures; concordance for the blinded quality control samples was 100%. Primers, probes, and conditions for genotyping assays are available upon request.

We used the χ^2^test to assess whether the genotypes for all seven SNPs were in Hardy-Weinberg equilibrium among the controls. We compared each type of skin cancer with the common control series to increase the statistical power. We evaluated the association between each genotype and skin cancer risk using unconditional logistic regression. An additive model was used to calculate the *p*-value on skin cancer risk according to an ordinal coding for genotype (0, 1 or 2 copies of SNP minor allele). For the four *FGFR2*SNPs and three *FGFR4*SNPs, haplotype frequencies and expected haplotype counts for each individual were estimated using a simple expectation-maximization algorithm, as implemented in SAS PROC HAPLOTYPE. The analyses of the associations between haplotypes and skin cancer risk were performed using the expectation-substitution technique \[[@B42]\]. All statistical analyses were two-sided and carried out using SAS V9.1 (SAS Institute, Cary, NC).

The Quanto statistical software version 1.2.3 was used for power calculation \[[@B43]\]. We calculated the power to detect the specified ORs at various allele frequencies of variant allele in additive models. The calculations were based on a two-sided alpha of 0.05. For melanoma (SCC or BCC), we have 80% power to detect an OR of 1.80 (1.72 or 1.70), 1.48 (1.42 or 1.41), and 1.35 (1.32 or 1.31) if the minor allele frequency is 5%, 15%, and 40%, respectively.

Results and discussion
======================

A detailed description of the characteristics of cases and controls in the skin cancer nested case-control study has been provided previously \[[@B44]\]. In brief, at the beginning of the follow-up of this nested case-control study, the nurses were between 43 and 68 years old (mean age, 58.7 years). The mean ages at diagnosis for incident melanoma, SCC, and BCC cases were 63.4, 64.7, and 64.0 years, respectively. A family history of skin cancer was a risk factor for all three types of skin cancer. Skin cancer cases had lighter pigmentation (skin color and hair color), more moles on the arms, higher cumulative sun exposure while wearing a bathing suit, and more lifetime severe sunburns that blistered than controls.

The genotype distributions of the seven SNPs evaluated in this study were in Hardy-Weinberg equilibrium among controls. The minor allele frequencies of these seven SNPs among controls in this study were similar to those from HapMap CEU data. We evaluated the main effect of each polymorphism across three types of skin cancer (Table [2](#T2){ref-type="table"}) and observed no significant associations between these seven SNPs and skin cancer risk. The multivariate analyses controlling for age and skin cancer risk factors showed results similar to the age-adjusted analyses (Additional file [1](#S1){ref-type="supplementary-material"}). Furthermore, we performed a global test to evaluate the difference in *FGFR2*and *FGFR4*haplotype frequencies between cases and controls (Table [3](#T3){ref-type="table"}) and found no significant associations with skin cancer risk, which was consistent with the results of the single SNP analyses presented in Table [2](#T2){ref-type="table"}.

###### 

Associations between the seven SNPs in the *FGFR2*and *FGFR4*genes and skin cancer risk

  SNP                    Melanoma            SCC    BCC                                            
  ---------------------- ------------------- ------ ------------------- ------ ------------------- ------
  *FGFR2*rs11200014      0.95 (0.77--1.19)   0.67   0.90 (0.74--1.10)   0.30   1.03 (0.85--1.26)   0.73
  *FGFR2*rs2981579       0.96 (0.77--1.19)   0.70   0.92 (0.75--1.12)   0.40   1.11 (0.91--1.36)   0.29
  *FGFR2*rs1219648       0.96 (0.77--1.20)   0.75   0.87 (0.71--1.07)   0.18   1.06 (0.87--1.29)   0.57
  *FGFR2*rs2420946       1.08 (0.85--1.38)   0.53   0.89 (0.72--1.10)   0.28   0.99 (0.81--1.21)   0.91
  *FGFR4*rs1966265\*\*   1.16 (0.90--1.48)   0.26   1.00 (0.79--1.26)   1.00   0.94 (0.74--1.19)   0.61
  *FGFR4*rs376618        0.88 (0.67--1.14)   0.33   1.04 (0.83--1.31)   0.73   0.87 (0.69--1.11)   0.27
  *FGFR4*rs351855        1.09 (0.87--1.38)   0.44   0.90 (0.73--1.12)   0.35   1.13 (0.93--1.39)   0.21

\*Unconditional logistic regression adjusted for age.

\*\*The SNP rs1966265 failed the assay and the rs12519145 was genotyped instead (r^2^= 0.8).

###### 

Haplotypes for the SNPs in the *FGFR2*and *FGFR4*genes and skin cancer risk

  *FGFR2*                                                                       Melanoma   SCC               BCC                                                                            
  --------------------------------------------------------- ------------- ----- ---------- ----------------- ------------------- ------------------- ------------------- ----- ------ ----- ------
                                                                                           Controls          Cases               Cases               Cases                                  
                                                                                                                                                                                            
  A                                                         B             C     D          n                 \%                  n                   \%                  n     \%     n     \%
                                                                                                                                                                                            
  0                                                         0             0     0          779               56.4                166                 55.3                286   59.8   270   55.1
                                                                                           Multivariate OR   1.00                1.00                1.00                                   
  1                                                         1             1     1          532               38.5                118                 39.3                177   37.0   196   40.0
                                                                                           Multivariate OR   1.06 (0.82--1.38)   0.90 (0.72--1.11)   1.06 (0.85--1.32)                      
  1                                                         1             0     0          25                1.8                 3                   1.0                 8     1.7    8     1.6
                                                                                           Multivariate OR   0.55 (0.16--1.89)   0.89 (0.39--2.00)   0.90 (0.40--2.05)                      
  1                                                         1             1     0          17                1.2                 8                   2.7                 3     0.6    6     1.2
                                                                                           Multivariate OR   2.42 (1.00--5.87)   0.46 (0.13--1.60)   1.03 (0.40--2.69)                      
  Rare \< 1%                                                29            2.1   5          1.7               4                   0.8                 10                  2.1                
                                                                                           Multivariate OR   0.80 (0.31--2.06)   0.41 (0.15--1.13)   0.98 (0.50--1.93)                      
                                                                                                                                                                                            
  A: rs11200014; B: rs2981579; C: rs1219648; D: rs2420946                                                                                                                                   
                                                                                                                                                                                            
                                                            ***FGFR4***                    **Melanoma**      **SCC**             **BCC**                                                    
                                                                                                                                                                                            
                                                                                           Controls          Cases               Cases               Cases                                  
                                                                                                                                                                                            
                                                            A             B     C          n                 \%                  n                   \%                  n     \%     n     \%
                                                                                                                                                                                            
                                                            0             0     1          446               29.7                118                 30.7                121   25.8   164   32.2
                                                                                           Multivariate OR   1.00                1.00                1.00                                   
                                                            0             0     0          391               26.0                89                  23.2                130   27.7   133   26.1
                                                                                           Multivariate OR   0.86 (0.63--1.17)   1.22 (0.92--1.62)   0.93 (0.71--1.21)                      
                                                            0             1     0          343               22.8                83                  21.7                113   24.0   106   20.9
                                                                                           Multivariate OR   0.91 (0.66--1.26)   1.21 (0.90--1.64)   0.82 (0.62--1.10)                      
                                                            1             0     0          293               19.5                84                  22.0                95    20.3   95    18.8
                                                                                           Multivariate OR   1.08 (0.78--1.49)   1.19 (0.88--1.62)   0.88 (0.66--1.18)                      
                                                            Rare \< 1%    30    2.0        9                 2.4                 10                  2.2                 10    1.9          
                                                                                           Multivariate OR   1.21 (0.49--2.96)   1.31 (0.55--3.10)   0.89 (0.37--2.16)                      
                                                                                                                                                                                            
  A: rs1966265\*; B: rs376618; C: rs351855                                                                                                                                                  

0, common allele; 1, rare allele.

Logistic regression adjusted for age.

*p*-values for global tests are \>0.05.

\*The SNP rs1966265 failed the assay and the rs12519145 was genotyped instead (r^2^= 0.8).

The potential contribution of the FGF/FGFR family to the development of skin cancer has been suggested. For example, the basic FGF (bFGF) alternatively named *FGF2*binds to distinct splice variants of the four FGFRs and acts as a potent activator in the proliferation and differentiation of melanocytes \[[@B45]\]. It has been noted that the combination of bFGF with ultraviolet (UV) light, the main risk factor for skin cancer, may lead to cutaneous melanoma induction \[[@B46]\]. In this study, we assessed the associations between the genetic variants in the *FGFR2*and *FGFR4*genes and the three types of skin cancer simultaneously with a modest sample size in each cancer type. Only one study has attempted to assess the relation of the *FGFR4*Gly388Arg with the progression of melanoma in melanoma patients, and observed that the *FGFR4*Arg388 allele was associated with tumor thickness and nodular malignant melanoma \[[@B26]\]. We did not observe a significant association of this allele with skin cancer risk. It seems that this SNP acts as a potential marker for the progression of skin cancer rather than susceptibility to skin cancer. Spinola et al. reported similar results for lung adenocarcinoma, i.e., that this allele revealed association with progression of cancer but a lack of association with the risk of cancer \[[@B33]\]. *FGFR2*possesses the largest genomic structure among the FGFR family, with at least 22 exons and 21 introns and has been implicated in distinct types of cancer \[[@B47]\]. Also, recent *in vitro*and *in vivo*studies showed that loss-of-function *FGFR2*mutations occur in a subset of melanomas \[[@B48]\]. It would be important to comprehensively examine the association of the common genetic variants in the entire *FGFR2*gene region with skin cancer risk.

Conclusion
==========

In conclusion, we did not detect any contribution of genetic variants in the *FGFR2*or *FGFR4*genes to inherited predisposition to skin cancer among Caucasian women.
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